Consequently, recommendations from various national and international medical societies, including the American College of Cardiology/American Heart Association [20] and the Endocrine Society [8], recommend that patients with refractory hypertension and hypertension with hypokalemia be evaluated for the presence of PA by measuring plasma aldosterone–renin activity or concentration. This evidence concerns the gene REN and Hypokalemia.